10 nominees · 11 ballot items.
Shareholders will vote on adoption of the 2025 statutory annual accounts; discharge of the Board for 2025; appointment of ten directors; authorizations for the Board to issue shares, restrict/exclude pre-emptive rights, repurchase and cancel ordinary shares; re-appointment of EY as auditor; amended remuneration for non-executive directors (increase in annual equity grant); a non-binding advisory 'say-on-pay' vote to approve Named Executive Officer compensation; and a non-binding advisory vote on the frequency of future say-on-pay votes.
Shareholders are asked to adopt the Company's 2025 Statutory Annual Accounts prepared under Dutch law and IFRS as adopted by the EU.
This proposal asks shareholders to adopt NXP’s 2025 Statutory Annual Accounts, which are the financial statements prepared under Dutch law and IFRS as adopted by the EU and which are required to be submitted to the AGM by Dutch law. Management explains that NXP also prepares US GAAP financial statements for SEC reporting, but that Dutch corporate law obliges the company to produce statutory accounts for shareholder adoption. The statutory accounts include EY Accountants B.V.’s report, offering independent assurance and forming part of the statutory annual report posted on the investor website. Adoption is a routine but legally necessary step that provides formal shareholder approval of the company’s statutory financial statements and may limit retrospective claims related to those disclosed items. The board recommends a vote FOR, arguing that adoption satisfies legal compliance and transparency objectives and confirms the financial reporting presented to shareholders. There is limited governance controversy here—this is a standard item in Dutch public companies and does not affect operational policy or capital structure. Investors should view this as a governance housekeeping matter that nevertheless provides legal closure on the year’s statutory reporting and signals the board’s confidence in the presented accounts. The recommendation is supported by the external auditor’s included report, which shareholders can review in the statutory annual report. Given its routine and compliance nature, this proposal is unlikely to involve material trade-offs for investors beyond reviewing the underlying audited financials.
Shareholders are asked to discharge the members of the Board for their performance and responsibilities during fiscal year 2025, covering matters disclosed in the 2025 Statutory Annual Report or otherwise publicly disclosed at the time of the resolution.
This management proposal requests shareholder approval to discharge the board members for actions taken and responsibilities performed during fiscal year 2025, a standard Dutch practice that, if approved, limits the scope for shareholders to pursue certain claims arising from matters disclosed in the statutory annual report or otherwise publicly disclosed. Management frames the discharge narrowly to apply only to disclosed matters, which is consistent with customary Dutch practice and provides legal certainty for directors following the reporting period. The board recommends a vote in favor to formalize shareholder acceptance of the company’s stewardship and implemented disclosures. For institutional investors, discharge votes serve as an accountability checkpoint—while often routine, they can become contentious if serious undisclosed or controversial matters exist; in this case the filing identifies no such controversies. Approving discharge typically signals investor confidence in the board’s oversight and in the audited disclosures for the year. Given the technical legal effect (limiting retroactive claims related to disclosed matters) and the board’s recommendation, the practical consequence for shareholders is procedural ratification rather than an operational change. Investors should review the statutory report and auditor commentary for substantive issues before voting, but absent such concerns the board’s justification is standard governance practice.
Appointment (re-appointment) of ten current directors nominated by the Board to serve until the end of the 2027 AGM.
Authorize the Board for 18 months to issue ordinary shares and grant rights to acquire ordinary shares up to 10% of issued share capital to provide flexibility for financing, acquisitions or other strategic purposes.
This management proposal seeks shareholder authorization to permit the Board to issue ordinary shares and grant rights to acquire shares up to 10% of issued share capital over an 18-month period. Management argues the authorization is prudent to allow the company to respond quickly to financing, acquisition, convertible note issuance or other strategic needs without the delay and expense of convening a shareholder vote each time. The filing acknowledges the dilution risk and potential share-price impact and therefore limits the authorization to 10% and to a specific 18-month window, reflecting typical Dutch practice. From a governance perspective, granting this authority increases management flexibility but reduces shareholder pre-approval for future issuances, so stewardship-minded investors will weigh the company’s capital needs, historical capital return (noted $22.7 billion returned since 2016) and use-of-proceeds discipline. The Board’s recommendation and discussion of prior authorization lapsing if approved signals continuity in capital governance. Analysts should consider the company’s balance sheet, current treasury holdings and stated use cases (acquisitions, financing, employee plans) when assessing dilution risk. Overall the proposal is standard for a large-cap technology company seeking optionality; prudent investors will monitor post-approval disclosures describing any actual issuances and the rationale for their use.
Authorize the Board for 18 months to restrict or exclude shareholders’ pre-emptive rights in connection with any issue of shares or grant of rights made under the authorization in Item 4.
This management resolution asks shareholders to permit the Board to restrict or exclude statutory pre-emptive rights that would otherwise allow existing shareholders to subscribe pro rata to new issues of shares or rights. Management links this authorization to the issuance power in Item 4, arguing that the ability to limit or remove pre-emptive rights is necessary in certain strategic situations (e.g., rapid financings or acquisitions) where offering subscription rights to all shareholders may be impracticable. The proposal is time-limited (18 months) and tied to a specific issuance cap (10%), which mitigates some dilution concerns; nevertheless, excluding pre-emption rights reduces shareholder control over future equity dilution. Investors should evaluate the company’s historical use of dilutive authority and governance safeguards, such as board oversight and disclosure commitments, when deciding whether to support such delegations. From a corporate law standpoint this is a common Dutch practice to provide execution flexibility; the board’s recommendation emphasizes practical advantages for execution speed. For fiduciary-focused shareholders, the key evaluation is whether management will use these powers sparingly and with clear disclosure of any future issuances. Overall, the authorization is standard but warrants post-approval monitoring of actual use and rationale.
Authorize the Board for 18 months to repurchase up to an additional 10% of issued share capital (subject to treasury share limits) to return capital, manage liquidity, and cover share-based compensation obligations.
This management proposal renews shareholder authorization for the Board to repurchase ordinary shares for an 18-month period, seeking flexibility to return capital, demonstrate confidence, provide liquidity and meet share-based compensation needs. The proposed ceiling is an additional 10% of issued share capital (April 10, 2026 basis), subject to a treasury share limit (total treasury shares not to exceed 20% of issued share capital), reflecting customary legal and market safeguards. The company cites a long history of capital returns (about $22.7 billion since 2016) and current treasury holdings of ~8% as context for this request, signaling an established repurchase program rather than a new strategic pivot. Execution mechanics are standard—open market, negotiated purchases, self-tenders and accelerated repurchases—with pricing limits up to 110% of VWAP to permit practical execution. From a shareholder perspective, repurchases can be accretive and efficient compared with dividends but may also reflect limited alternative investment opportunities; hence investors typically assess this authority by reviewing balance-sheet strength, capital allocation consistency, and disclosure of planned usage. The board’s recommendation and the explicit caps and methods help mitigate governance concerns, but shareholders should monitor actual repurchase activity and its impact on leverage and capital allocation.
Authorize the Board to cancel any ordinary shares held by the Company or repurchased under Item 6, resulting in a reduction of issued ordinary shares, subject to Dutch law timing rules.
This management proposal asks shareholders to empower the Board to cancel treasury shares held by the company or repurchased under the repurchase authorization, enabling an actual reduction in issued share capital. The authority is limited by Dutch law timing constraints (cancellation cannot take effect earlier than two months after the resolution and applies per tranche) and by the practical limit that cancellations cannot exceed the number of treasury shares held or repurchased. Management frames this as a complementary action to repurchases (Item 6), allowing the company to permanently retire shares not needed to satisfy share-based compensation or other obligations and thus potentially enhance per-share metrics. From a governance perspective, cancellations are a common mechanism to implement share buyback strategies fully, but shareholders should monitor that cancellations are used to support long-term value rather than obfuscate dilution or cover poor operational performance. The board recommends approval citing alignment with capital-return strategy. Investors will consider balance-sheet effects, the company’s ongoing capital needs, and disclosure of any planned cancellations when evaluating the vote.
Re-appoint EY Accountants B.V. as the Company's independent auditor for the 2026 fiscal year and continue the Audit Committee's pre-approval processes for audit and permitted non-audit services.
Approve an increase in the annual equity grant for non-executive directors from $225,000 to $240,000; no other changes to cash remuneration.
This management proposal requests shareholder approval to amend non-executive director remuneration by increasing the annual equity grant value from $225,000 to $240,000, with no change to cash fees. The Human Resources and Compensation Committee, supported by Mercer’s benchmarking analysis, presents this increase as a measured adjustment to remain competitive in attracting and retaining board talent given market practice and peer comparators. From a governance standpoint, modest increases in director equity are commonly used to align directors with shareholder interests while limiting cash outflows; the proposal retains the existing structure where equity vests and is subject to ownership guidelines. Shareholders should evaluate the peer benchmarking, historical changes, and the board’s rationale about retention and recruitment needs before voting. The proposal appears limited in scope (a $15,000 increase) and unlikely to materially affect shareholder dilution or executive pay dynamics, but it signals the board’s attention to market alignment. The board recommends FOR; investors concerned with governance should ensure continued transparency about director independence, committee oversight, and alignment with long-term shareholder value when approving changes to director compensation.
Non-binding advisory vote to approve the compensation of the Named Executive Officers as disclosed in the CD&A, compensation tables and related narrative disclosures.
This proposal solicits a non-binding advisory shareholder vote to approve NXP’s Named Executive Officer compensation as disclosed in the CD&A and associated tables, a standard 'say-on-pay' item under Section 14A. Management frames compensation as heavily performance‑based and aligned with long-term shareholder interests—highlighting AIP structure, PSUs tied to relative TSR, and retention-focused RSUs—while noting pay-for-performance outcomes for 2025 (AIP payouts at 30.8% of target and PSUs vesting at 50% for the 2023 grant). The Board and HRCC emphasize use of independent consultants, shareholder engagement, clawback provisions, double-trigger change-in-control protections and executive ownership guidelines to support alignment and responsible risk management. Because the vote is advisory, its practical effect is reputational; the HRCC and Board commit to reviewing results and considering shareholder feedback in future compensation design. Institutional investors should assess the degree to which realized pay reflected company performance in 2025 and whether plan design and governance processes adequately align incentives with sustainable value creation. Given the Board’s recommendation and the documented pay-for-performance mechanics, investors seeking change should engage with the company rather than expect immediate binding consequences from a failed advisory vote.
Non-binding advisory vote for shareholders to indicate preference for the frequency (1, 2 or 3 years) of future advisory votes on NEO compensation; the Board recommends an annual (1 year) vote.
This management proposal is the required periodic advisory vote on how often shareholders should be asked to cast non-binding 'say-on-pay' votes—choices being once every one, two or three years. The Board recommends an annual (one-year) frequency to ensure shareholders can regularly express views on executive pay and for the HRCC and Board to receive timely feedback for compensation governance. Because the outcome is advisory and decided by plurality, selecting annual votes reinforces more frequent engagement but does not change binding governance rules. For investors, annual votes offer more frequent opportunities to express concerns or support, which can be meaningful for companies undergoing rapid strategic or leadership changes—NXP experienced a CEO transition in 2025. The Board’s explicit recommendation and commitment to review results means investor sentiment will be considered in future compensation discussions. Overall, the proposal is procedural but carries governance importance insofar as it sets the cadence of shareholder feedback on pay practices.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | FMR LLC | 9.13% | 23,058,567 | $4.5B |
| 2 | JPMORGAN CHASE CO | 6.04% | 15,244,503 | $2.9B |
| 3 | WELLINGTON MANAGEMENT GROUP LLP | 4.62% | 11,669,051 | $2.3B |
| 4 | STATE STREET CORP | 4.36% | 10,997,044 | $2.2B |
| 5 | BlackRock, Inc. | 4.07% | 10,282,664 | $2.0B |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 3.20% | 8,077,896 | $1.6B |
| 7 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 2.18% | 5,496,072 | $1.1B |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.93% | 4,878,684 | $956M |
| 9 | VAN ECK ASSOCIATES CORP | 1.73% | 4,378,316 | $862M |
| 10 | Pictet Asset Management Holding SA | 1.52% | 3,842,220 | $756M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.